Focused On-demand Library for Protein Wnt-7a

Focused On-demand Libraries - Reaxense Collaboration

Explore the Potential with AI-Driven Innovation

The specialised, focused library is developed on demand with the most recent virtual screening and parameter assessment technology, guided by the Receptor.AI drug discovery platform. This approach exceeds the capabilities of traditional methods and offers compounds with higher activity, selectivity, and safety.

We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.

In the library, a selection of top modulators is provided, each marked with 38 ADME-Tox and 32 parameters related to physicochemical properties and drug-likeness. Also, every compound comes with its best docking poses, affinity scores, and activity scores, providing a comprehensive overview.

We utilise our cutting-edge, exclusive workflow to develop focused libraries for receptors.

Fig. 1. The sreening workflow of Receptor.AI

It features thorough molecular simulations of the receptor within its native membrane environment, complemented by ensemble virtual screening that considers its conformational mobility. For dimeric or oligomeric receptors, the full functional complex is constructed, and tentative binding sites are determined on and between the subunits to cover the entire spectrum of potential mechanisms of action.

Key features that set our library apart include:

The Receptor.AI platform integrates extensive information about the target protein, such as historical experiments, academic research, known ligands, and structural insights, thereby increasing the likelihood of identifying highly relevant compounds.
The platform’s sophisticated molecular simulations are designed to discover potential binding sites, ensuring that our focused library is optimal for the discovery of allosteric inhibitors and binders for cryptic pockets.
With over 50 customisable AI models, verified through extensive testing in commercial drug discovery and research, Receptor.AI is efficient, reliable, and precise. These models are essential in the production of our focused libraries.
Receptor.AI not only produces focused libraries but also provides full services and solutions at every stage of preclinical drug discovery, with a success-based pricing structure that aligns our interests with the success of your project.

partner

Reaxense

upacc

O00755

UPID:

WNT7A_HUMAN

Alternative names:

Alternative UPACC:

O00755; Q96H90; Q9Y560

Background:

Protein Wnt-7a, encoded by the gene with accession number O00755, is a pivotal ligand in the Wnt/beta-catenin signaling pathway. It plays a crucial role in embryonic development, influencing limb patterning, skeletal formation, and urogenital tract development. Additionally, it is essential for central nervous system angiogenesis, blood-brain barrier regulation, and neural stem cell proliferation.

Therapeutic significance:

Given its involvement in Limb pelvis hypoplasia aplasia syndrome and Fuhrmann syndrome, Protein Wnt-7a represents a promising target for therapeutic intervention. Understanding the role of Protein Wnt-7a could open doors to potential therapeutic strategies, particularly in addressing congenital limb malformations and joint dysplasia.